Expert view: Why you should use 3D models for high-throughput drug development screens
Posted: 10 September 2020 | Horizon Discovery | No comments yet
The clinical success rate of new oncology drugs is low compared to other diseases. One contributing factor is likely to be the testing systems used, particularly two-dimensional (2D) monolayer assay formats, which are the traditional mainstay of high-throughput compound screening.
Although 2D monolayer assays have aided the registration of successful drugs, it is increasingly recognised that 2D assays do not model key aspects of the three-dimensional (3D) tumour environment. The adoption of high-throughput screening approaches using 3D assays to complement 2D approaches could therefore substantially improve the identification and clinical applicability of new cancer therapies.
Related topics
Assays, High-Throughput Screening (HTS), Screening
Related organisations
Horizon Discovery